Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with
locally recurrent or metastatic dermatofibrosarcoma protuberans (DFSP) or transformed
fibrosarcomatous DFSP (a type of soft tissue sarcoma). Imatinib mesylate may stop the growth
of tumor cells by blocking the enzymes necessary for their growth